Oncology Is Booming But Cost Outlook Is Grim, IMS Says
The cost of oncology therapeutics and supportive care drugs grew 11.5% to $107bn in 2015 at constant exchange rates and is expected to reach $150bn globally in 2020, according to a new IMS report.
You may also be interested in...
Rebates have become industry's go-to for securing market access for drugs in competitive therapeutic areas in the US. But as payers push back, competitive rebating is intensifying and eating into the bottom line.
The American Society of Clinical Oncology (ASCO) asked the question "What is a cancer drug's true value?" and in four very specific treatment situations the organization's Value in Cancer Care Task Force supplied an answer: It depends.
Pfizer's COVID-19 vaccine is sure to dominate the third quarter results call, with everything from data to widescale distribution and the potential financial reward on the minds of investors and the public.